Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oramed Pharmaceuticals has received approval from the Institutional Review Board committee of Hadassah Medical Center in Jerusalem to conduct a Phase IIA study of its oral insulin on diabetic volunteers.
Subscribe to our email newsletter
This Phase IIA study is designed to evaluate the safety and efficacy of Oramed’s oral insulin capsule on Type II diabetic volunteers. This study is slated to begin in the second quarter of 2008. The trials are expected to last several months.
Nadav Kidron, CEO of Oramed, said: “Oramed’s oral insulin aims to revolutionize the current methods of treating diabetes.”